Clinical trials: Transfusion Blood
Heart Disease, Lung Disease
Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)
This is a pilot study that seeks to evaluate the feasibility and safety of using a TEG algorithm in addition to traditional laboratory tests to guide transfusion and coagulation management of ECMO patients.
- Trial name
- NCT02887820
- Testing
- Thromboelastograph
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stephen Esper
Myelodysplastic Syndromes, Anemia
A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion
The purpose of this study is to demonstrate that Epoetin alfa treatment reduces red blood cell transfusions in anemic patients with myelodysplastic syndromes (MDS).
- Trial name
- NCT00695396
- Testing
- Epoetin alfa
- Volunteers
- 25 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Neonatal Anemia
Red Blood Cell (RBC) Survival Following Transfusion in Infants
OUR OVERALL HYPOTHESIS is that post-transfusion survival of allogeneic and autologous RBCs can be accurately quantified in anemic human infants using biotin-labeled RBCs combined with mathematical modeling that adjusts for…
- Trial name
- NCT00731588
- Testing
- Transfused Biotin RBCs - Adults Phase I, Transfused Biotin RBCs - Infants Phase II, Transfused Biotin RBCs - Infants Phase III
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- John A Widness
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
This pilot clinical trial compares the safety of two different platelet transfusion "thresholds" among patients with blood cancer or treatment-induced thrombocytopenia whose condition requires anticoagulant medication (blood…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03195010
- Testing
- Platelet Transfusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fred Hutchinson Cancer Center
Hemoglobinopathies, Sickle Cell Disease
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
The purpose of this study is to determine if treatment with reduced-dose busulfex, fludarabine and alemtuzumab (CAMPATH) followed by sten cell infusion will allow for donor stem cells to grow in patients with hemoglobinopathies…
- Conditions
- Hemoglobinopathies, Sickle Cell Disease, Thalassemia
- Trial name
- NCT00153985
- Testing
- Busulfex, Fludarabine, Alemtuzumab
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Dana-Farber Cancer Institute
Hemostasis
In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)
This primary aim of this study is to compare the in vivo effects of fibrinogen concentrate and cryoprecipitate on the neonatal fibrin network after surgery with cardiopulmonary bypass to develop effective and safe strategies for…
- Trial name
- NCT03932240
- Testing
- Fibrinogen Concentrate (FC), Cryoprecipitate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Primary Myelofibrosis, Anemia
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
This is a Phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept in subjects with MPN-associated myelofibrosis and anemia with and without RBC-transfusion dependence.
- Trial name
- NCT03194542
- Testing
- Luspatercept
- Where
- 47 sites in United States, France and 2 more
- Volunteers
- 95 people
- Sponsor
- Celgene
Type 1 Diabetes Mellitus
Umbilical Cord Blood Infusion to Treat Type 1 Diabetes
While this study is now completely enrolled, we do hope to develop a "next generation" cord blood based study sometime in early 2009.
- Trial name
- NCT00305344
- Testing
- Autologous Umbilical Cord Blood Transfusion, Cord blood
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Florida
Diffuse Large B-cell Lymphoma
Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
Treatment of adult patients with Diffuse Large B-cell Lymphoma (DLBCL), relapsed or refractory to previous CHOP-R (or CHOP-R like regimen) front line therapy, relapsed or refractory to second or subsequent salvage therapies which…
- Trial name
- FIL_PanAL10 (NCT01523834)
- Testing
- Panobinostat
- Where
- 10 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients
Therapeutic plasma exchange (TPE) has been proposed as a rescue therapy in critically ill COVID-19 patients. The aim of this study is to determine whether combining TPE with convalescent plasma (CVP) transfusion early during the…
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, Acute Respiratory Failure, Acute Respiratory Distress Syndrome
- Trial name
- NCT04973488
- Testing
- Therapeutic plasma exchange
- Where
- Romania
- Volunteers
- 38 people
- Sponsor
- Novacescu Alexandru
Myelodysplastic Syndrome (MDS)
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)
This study assessed the efficacy and safety of LBH589 as single agent and in combination with ESA in red blood cell transfusion-dependent Low and Int-1 MDS patients being either refractory to ESA or with a low probability of…
- Trial name
- GEPARD (NCT01034657)
- Testing
- LBH589, Epoetin Alfa
- Where
- 12 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Hemorrhagic Shock, Acute Blood Loss Anemia
Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
Adult male patients brought to the emergency department as Level A trauma activations who are receiving emergency blood transfusion. Objectives 1.
- Conditions
- Hemorrhagic Shock, Acute Blood Loss Anemia, Traumatic Brain Injury
- Trial name
- NCT05081063
- Testing
- Routine labs
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Loma Linda University
Postpartum Hemorrhage
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
The aim of this study is to evaluate the impact of a rotational thromboelastometry (ROTEM®)-based transfusion protocol during postpartum hemorrhage (PPH) after vaginal or cesarean delivery.
- Trial name
- NCT03064152
- Testing
- Rotational Thromboelastometry
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Acute Coagulopathy
Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma
The purpose of this study is to compare rapid thrombelastography (r-TEG) with conventional coagulation testing for diagnosing and treating coagulation abnormalities in severely injured patients who are likely to require…
- Trial name
- NCT01536496
- Testing
- Blood product transfusion based on conventional coagulation tests., Blood product transfusion based on rapid thrombelastography (r-TEG) results.
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Denver Health and Hospital Authority
Hip Fracture
Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?
Does tranexamic acid improve the perioperative care of those patients treated surgically for hip fracture by decreasing the proportion of patients requiring transfusion and decreasing total perioperative bleeding.
- Trial name
- NCT01714336
- Testing
- tranexamic acid
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
COVID-19
VA CoronavirUs Research and Efficacy Studies-1
The purpose of this study is to determine if treatment with convalescent plasma improves the clinical outcomes of Veterans who are hospitalized and require supplemental oxygen due to COVID-19.
- Trial name
- VACURES-1 (NCT04539275)
- Testing
- Convalescent Plasma
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- VA Office of Research and Development
Coronary Artery Disease, Coronary Artery Bypass
Impact of Fluid Restriction Policy in Reducing the Use of Red Cells in Cardiac Surgery
The investigators' hypothesis is that restriction of circulating fluids in comparison to a liberal fluid administration policy would lead to a reduction of allogenic red blood cells exposure in patients undergoing cardiopulmonary…
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass, Erythrocyte Transfusion
- Trial name
- NCT00600704
- Testing
- Fluid Restriction Policy, Free fluid infusion
- Where
- Greece
- Volunteers
- 192 people
- Sponsor
- Larissa University Hospital
Traumatic Shock
AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock
Trauma patients, who are transfused with multiple blood products to treat shock due to blood loss, frequently develop inappropriately low vasopressin levels.
- Trial name
- AVERTShock (NCT01611935)
- Testing
- Vasopressin
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma
FM 140 vs FM100 Study in Patients With Multiple Myeloma
The goal of this clinical research study is to learn if there is a difference in transplant outcomes between two different doses of melphalan given in combination with fludarabine followed by transfusion of a related or unrelated…
- Trial name
- NCT00505895
- Testing
- Melphalan, Fludarabine, Stem Cell Infusion
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Blood Transfusion, Rhesus Isoimmunisation Due to Anti-D
RhD+ Blood Transfusion to Asian-type DEL Recipients
Red blood cells (RBCs) from Asian-type DEL blood group express very weak RhD antigen and are falsely typed as RhD-negative blood group in routine RhD testing.
- Conditions
- Blood Transfusion, Rhesus Isoimmunisation Due to Anti-D, Blood Group Antigen Abnormality
- Trial name
- NCT03727230
- Testing
- Blood transfusion
- Where
- 10 sites in China
- Volunteers
- 54 people
- Sponsor
- Guangzhou Blood Center